Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with...
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of...
TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)...
Dr. Raymond Turner is a board-certified endovascular neurosurgeon with more than 20 years of surgical practice Dr. Raymond Turner Dr. Turner...
New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challengesSEATTLE and VANCOUVER,...
ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based...
LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which...
Company received $4,000,000 of additional loan proceeds Maturity date extended to September 18, 2030 Capital infusion bolsters balance sheet for...
WEST PALM BEACH, FL, Sept. 22, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTCID: FOXO) (“FOXO” or the “Company”), announces the closing of...
Investigator-initiated randomized controlled combination trial published in the International Journal of Dermatology confirms its superiority to monotherapy, fueling continued market...
DALLAS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), announced today that its wholly owned subsidiary,...
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key...
Potential Multi-Billion Dollar as Sample Deliveries NearDENVER, Sept. 22, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated...
- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian...
Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companiesSUNNYVALE, Calif., Sept. 22, 2025...
CHICAGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global...
CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company...
- Patent portfolio secures innovation for the future of heart replacement - TUCSON, Ariz., Sept. 22, 2025 (GLOBE NEWSWIRE) --...
GARDEN CITY, N.Y., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a...
Phase 2 ASCEND trial of solengepras, a novel, non-dopaminergic GPR6 inhibitor, showed evidence of potential benefit in functional and non-motor...